Results 181 to 190 of about 3,296 (215)
Some of the next articles are maybe not open access.
Cancer Prevention Research, 2011
Abstract Patients with Barrett's esophagus (BE) and dysplasia are candidates for chemopreventive strategies to reduce cancer risk. We determined the effects of difluoromethylornithine (DMFO) on mucosal polyamines, gene expression, and histopathology in BE. Ten patients with BE and low-grade dysplasia participated in a single-arm study of
Frank A, Sinicrope +8 more
openaire +2 more sources
Abstract Patients with Barrett's esophagus (BE) and dysplasia are candidates for chemopreventive strategies to reduce cancer risk. We determined the effects of difluoromethylornithine (DMFO) on mucosal polyamines, gene expression, and histopathology in BE. Ten patients with BE and low-grade dysplasia participated in a single-arm study of
Frank A, Sinicrope +8 more
openaire +2 more sources
Cancer Letters, 1987
The effect of the duration and sequence of inhibition of intestinal tumor formation in rats was studied to determine whether part time inhibition has any value. Four groups of male Sprague-Dawley rats were given 8 weekly s.c. injections of azoxymethane (AOM) 8 mg/rat. Three groups were given the inhibitor, difluoromethylornithine (DFMO) in the drinking
N D, Nigro, A W, Bull, M E, Boyd
openaire +2 more sources
The effect of the duration and sequence of inhibition of intestinal tumor formation in rats was studied to determine whether part time inhibition has any value. Four groups of male Sprague-Dawley rats were given 8 weekly s.c. injections of azoxymethane (AOM) 8 mg/rat. Three groups were given the inhibitor, difluoromethylornithine (DFMO) in the drinking
N D, Nigro, A W, Bull, M E, Boyd
openaire +2 more sources
Prevention of metastasis of intraocular melanoma in mice treated with difluoromethylornithine
Graefe's Archive for Clinical and Experimental Ophthalmology, 1992The antimetastatic potential of a novel chemotherapeutic agent, alpha-difluoromethylornithine (DFMO), was evaluated in a murine model of intraocular melanoma. In vivo studies demonstrated that DFMO retarded the growth and spontaneous metastasis of murine intraocular melanomas.
G, Sanborn +3 more
openaire +2 more sources
Growth inhibition of a prostate tumor by α-difluoromethylornithine and by cyclophosphamide
Cancer Letters, 1982The effects of the ornithine decarboxylase suicide substrate, difluoromethylornithine (DFMO), and of cyclophosphamide, individually and in combination, on the growth of the R3327MAT-Lu prostate derived tumor were determined. DFMO decreased the growth rate and resulted in a 75% reduction in DNA content compared to the control group.
W D, Heston, D, Kadmon, W R, Fair
openaire +2 more sources
Effect of difluoromethylornithine on atrial natriuretic peptide in rat atria
Regulatory Peptides, 1993Polyamines are aliphatic cations known to have a role in cellular growth and differentiation. In this study, difluoromethylornithine (DFMO), an inhibitor of polyamine synthesis, was used to investigate its effect on atrial natriuretic peptide (ANP) in atria of rat.
U R, Tipnis, J B, Gentry, J, Gutkowska
openaire +2 more sources
Inhibition of Leishmania Species by α-Difluoromethylornithine
1989DL- α-difluoromethylornithine (DFMO) is a specific, irreversible inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme in trypanosome polyamine biosynthesis (reviewed in 1). DFMO cures experimental infections of African trypanosomiasis, and is in phase 1 clinical trials2. Although the mechanism of selective toxicity is incompletely known,
Jan S. Keithly, Alan H. Fairlamb
openaire +1 more source
Effects of Human Interferon and α-Difluoromethylornithine on T47D Cells
Journal of Interferon Research, 1986The effect of human interferon (IFN) and alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of eukaryotic ornithine decarboxylase, on the rate of DNA synthesis and the increase of ornithine decarboxylase activity of T47D cells was examined. It was found that IFN or DFMO alone causes little or appreciable inhibition of the [
D A, Kyriakidis, A, Kortsaris
openaire +2 more sources
Kinetics of α-difluoromethylornithine: An irreversible inhibitor of ornithine decarboxylase
Clinical Pharmacology and Therapeutics, 1981We gave alpha-difluoromethylornithine (DFMO), a selective, irreversible inhibitor of ornithine decarboxylase, to six health men in single intravenous doses of 5 and 10 mg/kg body weight and oral doses of 10 and 20 mg/kg. Plasma concentrations were monitored during the 24 hr after each dose.
K D, Haegele +4 more
openaire +2 more sources
Affinity labeling of purified ornithine decarboxylase by α-difluoromethylornithine
Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1982Ornithine decarboxylase (L-ornithine carboxy-lyase, EC 4.1.1.17) purified from rat liver was affinity-labeled by alpha-[5-14C]difluoromethylornithine. On analysis by SDS-polyacrylamide gel electrophoresis, the radioactivity migrated as a single major peak that coincided with a single protein band of Mr 50,000.
T, Kameji, S, Hayashi
openaire +2 more sources
Effects of α-difluoromethylornithine on pancreatic growth induced by caerulein
Regulatory Peptides, 1984The role of ornithine decarboxylase and of polyamines was investigated on caerulein-induced pancreatic growth by the use of alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase. By itself, DFMO did not affect the pancreatic gland at all but when combined with caerulein, it reduced the increases in ...
O, Benrezzak, J, Morisset
openaire +2 more sources